For:
Severe Diarrhea and Flushing Associated With Carcinoid Syndrome
Important Safety Information

Warnings and Precautions: Gallbladder abnormalities may occur: Patients should be monitored periodically. Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be...

See More

Indication Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated. In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.

Access

Universal Co-Pay Program

Novartis Universal Co-pay Card

Patients may be eligible for immediate co-pay savings on their next prescription of Sandostatin® LAR Depot (octreotide acetate for injectable suspension).

  • Commercially insured patients pay $25 per month
  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*

*Limitations apply. Patient must have commercial insurance. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full terms and conditions, visit www.CoPay.NovartisOncology.com or call 1-877-577-7756.

Tell your patients to call 1-877-577-7756 or visit www.CoPay.NovartisOncology.com.

Terms and Conditions: This offer is valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash payments, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. The card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend this program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2018. Additional Terms and Conditions may apply.

Patient Assistance Now Oncology

Patient Assistance Now Oncology

Patient Assistance Now Oncology (PANO) is a support center consisting of insurance specialists and case managers who provide access to information regarding an array of services. Consider PANO your first stop for information about Novartis Oncology Patient Support programs. Dedicated support specialists help direct callers to the services that best fit their needs.

Support for patients includes:

  • Insurance benefits verification, including information on denials and/or appeals
  • Information about financial assistance that may be available
  • Patient Support Counselors who are able to provide information in over 160 languages
  • Dedicated case managers with a private extension for you to reach them directly when needed
  • A combination of PANO case managers and/or field reimbursement managers are available to help depending on the complexity of a patient's case

To learn more, call 1-800-282-7630 or visit www.HCP.Novartis.com/Access/.

Reimbursement FAQs

Q: When can I call the PANO Hotline (1-800-282-7630)? 

A: Monday through Friday, 9 AM to 8 PM ET

Q: Do private medical insurance plans and Medicare cover Sandostatin® LAR Depot (octreotide acetate for injectable suspension)?

A: Yes, most do. To learn more, call the PANO Hotline (1-800-282-7630).

Q: Do private medical insurance plans cover Sandostatin® (octreotide acetate) Immediate-release Injection?

A: Yes, most do. For more information, call the PANO Hotline (1-800-282-7630).

Q: What can I do if a claim is denied?

A: There are several things you can do. First, you can review the patient's EOB form and document the medical necessity for the patient. For more information, call the PANO Hotline (1-800-282-7630).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions:

  • Gallbladder abnormalities may occur: Patients should be monitored periodically.
  • Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should be monitored when Sandostatin LAR Depot treatment is initiated or when the dose is altered. Antidiabetic treatment should be adjusted accordingly. 
  • Thyroid Function: Hypothyroidism may occur. Baseline and periodic assessment of thyroid function (TSH, total and/or free T4) is recommended.
  • Cardiac Function: Bradycardia, arrhythmia, conduction abnormalities, and other EKG changes may occur. The relationship of these events to octreotide acetate is not established because many of these patients have underlying cardiac disease. Use with caution in at-risk patients.
  • Nutrition: Octreotide may alter absorption of dietary fats. Monitoring of vitamin B12 levels is recommended during therapy with Sandostatin LAR Depot. Patients on total parenteral nutrition (TPN) and octreotide should have periodic monitoring of zinc levels.  

Drug Interactions: The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution. 

Adverse ReactionsThe most common adverse reactions occurring in patients receiving Sandostatin LAR Depot were biliary abnormalities (62%), injection site pain (20-50%), nausea (24-41%), abdominal pain (10-35%), fatigue (8-32%), headache (16-30%), hyperglycemia (27%), back pain (8-27%), constipation or vomiting (15-21%), dizziness (18-20%), sinus bradycardia (19%), pruritus (18%), URTI (10-18%), myalgia (4-18%), flatulence (9-16%), arthropathy (8-15%), rash (15%), generalized pain (4-15%), sinusitis (5-12%), conduction abnormalities (9%), hypoglycemia (4%), and arrhythmia (3%).

Please see full Prescribing Information.

Indication and Usage

Sandostatin® LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for:

  • Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
  • Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined.